Supportive care in children

Current Opinion in Oncology

Volumn 22, Issue 4, 2010, Pages 323-329

  Santolaya, María E ^a  

^a HOSPITAL LUIS CALVO MACKENNA   (Chile)

Author keywords

biomarkers; children; febrile neutropenia; high risk; low risk; sepsis

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CEFEPIME; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CYCLOSPORIN A; IMIPENEM; INTERLEUKIN 6; INTERLEUKIN 8; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ASPERGILLUS; BACTEREMIA; BACTERIAL INFECTION; CANCER PATIENT; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMBINATION CHEMOTHERAPY; DEATH; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; STAPHYLOCOCCUS AUREUS; SYSTEMIC MYCOSIS; VIRUS INFECTION;

BACTERIAL INFECTIONS; CHILD; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; PATIENT CARE MANAGEMENT; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 77953917510     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833a8752     Document Type: Review

References (55)

1. Patton G, Coffey C, Sawyer S, et al. Global patterns of mortality in young people: a systematic analysis of population health data. Lancet 2009; 374:881-892.
2. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol 2008; 25:385-392.
3. Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 2009; 27:525-544.
4. Rackoff W, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14:919-924.
5. Lehrnbecher T, Venzon D, de Haas M, et al. Assessment of measuring circulating levels of interleukin 6, interleukin 8, C Reactive Protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999; 29:414-419.
6. Klaasen RJ, Goodman TR, Pham B, et al. 'Low-risk' prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012-1019.
7. Santolaya ME, Alvarez A, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001; 19:3415-3421.
8. Santolaya ME, Alvarez A, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 2002; 35:678-683.
9. Oude-Nijhuis C, Kamps W, Daenen SE, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005; 20:7437-7444.
10. Wicki S, Keisker A, Aebi C, et al. Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy? Pediatr Blood Cancer 2008; 51:778-783.
11. Avabratha KS, Rau AT, Venkataravanamma P, et al. Significance of C-reactive protein during febrile neutropenia in pediatric malignancies. Indian Pediatr 2009; 46:797-799.
12. Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28:1064-1068.
13. Sakr Y, Sponholz C, Tuche F, et al. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36:396-407.
14. Martinez-Albarran M, de Perez-Molina JA, Gallegos-Castorena S, et al. Procalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer. Pediatr Hematol Oncol 2009; 26:414-425.
15. Semeraro M,ThomeeC, Rolland E, et al. A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 2010; 54:284-290.
16. te Poele EM, Tissing WJ, Kamps WA, de Bont ES. Risk assessment in fever and neutropenia in children with cancer: what did we learn? Crit Rev Oncol Hematol 2009; 72:45-55.
17. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J 2008; 27:538-543.
18. Diepold M, Noellke P, Duffner U, et al. Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever. BMC Infect Dis 2008; 6:8-28.
19. Basu S, Fernandez L, Fisher S, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23:7958-7966.
20. Paganini H, Aguirre C, Puppa G, et al. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109:2572-2579.
21. Santolaya ME, Alvarez A, Becker A, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenia episode. Pediatr Infect Dis J 2007; 26:794-798.
22. Paya E, Alvarez AM, Aviles CL, et al. Causative agents of bloodstream infections in children with neoplasm, in five hospitals of Santiago (1994-1998) [in Spanish]. Rev Med Chile 2001; 129:1297-1304.
23. Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 3:623-629.
24. Santolaya ME, Alvarez AM, Aviles CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalizations of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 2004; 22:3784-3832.
25. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 15:1296-1304.
26. Petti C. Detection and identification of microorganism by gene amplification and sequencing. Clin Infect Dis 2007; 44:1108-1114.
27. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukaemia: analysis of the prospective multiinstitutional clinical trial AML-BFM 93. Leukemia 2004; 18:72-77.
28. Tager FM, Zolezzi RP, Folatre BI, et al. Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: a prospective study. Rev Chil Infectol 2006; 23:118-123.
29. Lindblom A, Bhadri V, Soderhall S, et al. Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol 2010; 47:234-237.
30. Ramphal R, Grant RM, Dzolganovski B, et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26:700-704.
31. Holzinger D, Kühn J, Ehlert K, et al. HSV-1 viremia as a potential cause of febrile neutropenia in an immunocompromised child. J Pediatr Hematol Oncol 2010; 32:19-21.
32. De Pauw B, Walsh T, Donnelly P, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORT/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
33. Segal B. Aspergillosis. N Engl J Med 2009; 360:1870-1884.
34. Pappas P, Kauffman C, Andes D, et al. Clinical Practice Guidelines for the management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-3545.
35. Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008; 8:70.
36. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood haematological malignancies. Pediatr Hematol Oncol 2008; 25:291-299.
37. Pires CA, Petrilli AS, Carlesse FA, et al. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. J Microbiol Immunol Infect 2009; 42:141-147.
38. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55:436-444.
39. Uygun V, Karasu GT, Ogunc D, et al. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. Pediatr Blood Cancer 2009; 53:610-614.
40. Kobayashi R, Sato T, Nakajima M, et al. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol 2009; 31:270-273.
41. Erbey F, Bayram I, Yilma S, et al. Imipenem in the treatment of febrile neutropenic children. Asian Pac J Cancer Prev 2009; 10:921-924.
42. Inparajah M, Wong C, Sibbald C, et al. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. Pharmacotherapy 2010; 30:43-51.
43. Hamidah A, Rizal AM, Nordiah AJ, Jamal R. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2008; 49:26-30.
44. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
45. Mendes AV, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr 2007; 83:S54-63.
46. European Organization for Research and Treatment of Cancer (EORTC). International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163:951-958.
47. Paulus S, Dobson S, Rassekh S, et al. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices. J Pediatr Hematol Oncol 2009; 31:267-269.
48. Abe M, Kamijo T, Matsuzawa S, et al. High incidence of meropenem resistance among alpha-hemolytic streptococci in children with cancer. Pediatr Int 2009; 51:103-106.
49. Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32:36-43.
50. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk Febrile Neutropenia in children with malignant disease. Cancer 2003; 97:2493.
51. Paganini H, Rodriguez-Brieschcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management or children with cancer with lower risk febrile neutropenia. Cancer 2001; 91:1563-1567.
52. Gupta A, Swaroop C, Agarwala S, et al. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009; 31:635-641.
53. Cagol AR, de Castro Junior CG, Martins MC, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr 2009; 85:531-535.
54. Dommett R, Geary J, Freeman S, et al. Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. Eur J Cancer 2009; 45:2843-2849.
55. Elting L, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26:606-611.